Researchers from Saint Louis University have published their findings online in the Annals of Family Medicine.
Jeffrey Scherrer, Ph.D., and his co-authors speculate that findings may be explained by long-term opioid use of more than 30 days can lead to changes in neuroanatomy and low testosterone, among other possible biological explanations.
Opioid drugs in the study included codeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, oxycodone, oxymorphone, morphine, and pentazocine.
The relationship between opioid drugs and depression was independent of the known contribution of pain to depression. Accordingly, the study calls on clinicians to consider the contribution of opioid use when depressed mood develops in their patients.
“Opioid-related new onset of depression is associated with longer duration of use but not dose,” Scherrer wrote. “Patients and practitioners should be aware that opioid analgesic use of longer than 30 days imposes risk of new-onset depression.”
The study calls for additional research to identify which patients are most vulnerable to opioid-related depression.
Scherrer and his co-authors collected patient data from 2000-2012 from the Veterans Health Administration (VHA), Baylor Scott & White Health (BSWH), and the Henry Ford Health System (HFHS).
The data sets were comprised of 70,997 VHA patients, 13,777 BSWH patients and 22,981 patients from HFHS. The patients were new opioid users, ages 18 to 80, without a diagnosis of depression when they began taking medication.
The study expands on Scherrer’s previous study of VA patients and opioids to determine whether:
- taking an opioid for a longer period of time is associated with new-onset depression while controlling for dose;
- a higher dose of opioids is associated with new-onset depression after adjusting for duration;
- opioid analgesic use remains associated with new-onset depression after controlling for pain scores in VHA patient data; and
- results generalize to two independent health care populations.
Twelve percent of the VHA sample, nine percent of the BSWH sample and 11 percent of the HFHS sample experienced new-onset depression after opioid analgesic use.
“Findings were remarkably consistent across the three health care systems even though the systems have very different patient characteristics and demographics,” Scherrer said.
In all three patient populations, longer duration of opioid analgesic use was associated with new-onset depression after controlling for pain and daily morphine equivalent doses.
The authors note that research on the efficacy of opioids in depression treatment, while limited by small samples, short follow-up times, and lack of control groups, does not support opioids as an effective long-term treatment for depression.
Source: St. Louis University/EurekAlert